From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|October 13, 2021
Pharmacy Clinical Pearl of the Day: Guillain-Barre Syndrome
Author(s)Saro Arakelians, PharmD
In its most severe form, Guillain-Barre syndrome is a medical emergency.
Advertisement
Clinical Pearl of the Day: Guillain-Barre Syndrome
Guillain-Barre syndrome is a rare disorder in which the body's immune system attacks the nerves.
Insight:
- Weakness and tingling in the extremities are usually the first symptoms. These sensations can quickly spread, eventually paralyzing the entire body.
- In its most severe form, Guillain-Barre syndrome is a medical emergency.
- Most people with the condition must be hospitalized to receive treatment.
- Signs and symptoms of this syndrome include prickling; pins and needles sensation; weakness in the legs and unsteady walking; difficulty with facial movements, including speaking; double vision; severe pain that may feel achy; difficulty with bladder control; rapid heart rate; low or high blood pressure; and difficulty breathing.
- There are 3 types to this syndrome: acute inflammatory demyelinating polyradiculoneuropathy, Miller Fisher syndrome, and acute motor axonal neuropathy.
- Treatment options for this syndrome include plasma exchange (plasmapheresis), immunoglobulin therapy, pain relievers, physical therapy, and training with adaptive devices. This disease has no cure.
Sources:
Advertisement
Related to this article
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5